Zealand Pharma A/S. ZEAL
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Zealand Pharma A/S. shares you hold and we'll calculate your dividend payments:
Sign up for Zealand Pharma A/S. and we'll email you the dividend information when they declare.
Add Zealand Pharma A/S. to receive free notifications when they declare their dividends.
Your account is set up to receive Zealand Pharma A/S. notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Zealand Pharma A/S. dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0öre | — |
| 2007 | 0.0öre | 0% |
| 2008 | 0.0öre | 0% |
| 2009 | 0.0öre | 0% |
| 2010 | 0.0öre | 0% |
| 2011 | 0.0öre | 0% |
| 2012 | 0.0öre | 0% |
| 2013 | 0.0öre | 0% |
| 2014 | 0.0öre | 0% |
| 2015 | 0.0öre | 0% |
| 2016 | 0.0öre | 0% |
| 2017 | 0.0öre | 0% |
| 2018 | 0.0öre | 0% |
| 2019 | 0.0öre | 0% |
| 2020 | 0.0öre | 0% |
| 2021 | 0.0öre | 0% |
| 2022 | 0.0öre | 0% |
| 2023 | 0.0öre | 0% |
| 2024 | Sign Up Required | |
Zealand Pharma A/S. Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 15 January 2024
- 52 Week Low
- 0.0% on 15 January 2024
- Next Ex-Div-Date Countdown
- Sign Up Required
About Zealand Pharma A/S.
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- Denmark
- Share Price
- kr.710.50 (yesterday's closing price)
- Shares in Issue
- 71 million
- Market Cap
- kr.50.5bn
- 0
- Market Indices
- none
